CA3081983A1 - Substituted pyrazole compounds and methods of using them for treatment of hyperproliferative diseases - Google Patents
Substituted pyrazole compounds and methods of using them for treatment of hyperproliferative diseases Download PDFInfo
- Publication number
- CA3081983A1 CA3081983A1 CA3081983A CA3081983A CA3081983A1 CA 3081983 A1 CA3081983 A1 CA 3081983A1 CA 3081983 A CA3081983 A CA 3081983A CA 3081983 A CA3081983 A CA 3081983A CA 3081983 A1 CA3081983 A1 CA 3081983A1
- Authority
- CA
- Canada
- Prior art keywords
- optionally substituted
- cancer
- phenyl
- compound
- nr3g
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims abstract description 26
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract 6
- 230000003463 hyperproliferative effect Effects 0.000 title claims abstract 6
- NOIXNOMHHWGUTG-UHFFFAOYSA-N 2-[[4-[4-pyridin-4-yl-1-(2,2,2-trifluoroethyl)pyrazol-3-yl]phenoxy]methyl]quinoline Chemical class C=1C=C(OCC=2N=C3C=CC=CC3=CC=2)C=CC=1C1=NN(CC(F)(F)F)C=C1C1=CC=NC=C1 NOIXNOMHHWGUTG-UHFFFAOYSA-N 0.000 title description 2
- 201000010099 disease Diseases 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract 122
- 206010028980 Neoplasm Diseases 0.000 claims abstract 33
- 201000011510 cancer Diseases 0.000 claims abstract 28
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims abstract 4
- 101150105104 Kras gene Proteins 0.000 claims abstract 3
- 230000002401 inhibitory effect Effects 0.000 claims abstract 3
- 108010024636 Glutathione Proteins 0.000 claims abstract 2
- 230000015572 biosynthetic process Effects 0.000 claims abstract 2
- 230000022131 cell cycle Effects 0.000 claims abstract 2
- 239000003814 drug Substances 0.000 claims abstract 2
- 229960003180 glutathione Drugs 0.000 claims abstract 2
- 238000003786 synthesis reaction Methods 0.000 claims abstract 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 36
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 28
- 125000003709 fluoroalkyl group Chemical group 0.000 claims 27
- 125000004093 cyano group Chemical group *C#N 0.000 claims 19
- 229910052736 halogen Inorganic materials 0.000 claims 19
- 150000002367 halogens Chemical class 0.000 claims 19
- 125000004178 (C1-C4) alkyl group Chemical class 0.000 claims 18
- 125000000753 cycloalkyl group Chemical group 0.000 claims 18
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 15
- 125000001424 substituent group Chemical group 0.000 claims 14
- 206010025323 Lymphomas Diseases 0.000 claims 12
- 229910052757 nitrogen Inorganic materials 0.000 claims 12
- HCMJWOGOISXSDL-UHFFFAOYSA-N (2-isothiocyanato-1-phenylethyl)benzene Chemical compound C=1C=CC=CC=1C(CN=C=S)C1=CC=CC=C1 HCMJWOGOISXSDL-UHFFFAOYSA-N 0.000 claims 11
- 210000004027 cell Anatomy 0.000 claims 11
- 125000001072 heteroaryl group Chemical group 0.000 claims 11
- 125000005842 heteroatom Chemical group 0.000 claims 11
- 229910052760 oxygen Inorganic materials 0.000 claims 11
- 229910052717 sulfur Chemical group 0.000 claims 11
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 9
- 125000003118 aryl group Chemical group 0.000 claims 9
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 9
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims 9
- 229910052739 hydrogen Inorganic materials 0.000 claims 9
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 9
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 9
- 239000001301 oxygen Chemical group 0.000 claims 9
- 239000011593 sulfur Chemical group 0.000 claims 9
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims 8
- 125000003342 alkenyl group Chemical group 0.000 claims 8
- 125000000304 alkynyl group Chemical group 0.000 claims 8
- 239000001257 hydrogen Substances 0.000 claims 8
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 8
- -1 trifluoromethyl-substituted phenyl Chemical group 0.000 claims 8
- 210000003169 central nervous system Anatomy 0.000 claims 7
- FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical compound C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 claims 6
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 6
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims 6
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 claims 6
- 208000033755 Neutrophilic Chronic Leukemia Diseases 0.000 claims 6
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 claims 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 6
- 102000034527 Retinoid X Receptors Human genes 0.000 claims 6
- 108010038912 Retinoid X Receptors Proteins 0.000 claims 6
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 claims 6
- IYABWNGZIDDRAK-UHFFFAOYSA-N allene Chemical group C=C=C IYABWNGZIDDRAK-UHFFFAOYSA-N 0.000 claims 6
- 201000010902 chronic myelomonocytic leukemia Diseases 0.000 claims 6
- 201000010903 chronic neutrophilic leukemia Diseases 0.000 claims 6
- 208000011691 Burkitt lymphomas Diseases 0.000 claims 5
- 208000026876 intravascular large B-cell lymphoma Diseases 0.000 claims 5
- 201000005962 mycosis fungoides Diseases 0.000 claims 5
- 125000006726 (C1-C5) alkenyl group Chemical class 0.000 claims 4
- 125000006527 (C1-C5) alkyl group Chemical group 0.000 claims 4
- 108091008776 CNR14-like Proteins 0.000 claims 4
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims 4
- 201000007224 Myeloproliferative neoplasm Diseases 0.000 claims 4
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 claims 4
- 208000035475 disorder Diseases 0.000 claims 4
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 claims 4
- 125000003226 pyrazolyl group Chemical group 0.000 claims 4
- 125000004076 pyridyl group Chemical group 0.000 claims 4
- 206010041823 squamous cell carcinoma Diseases 0.000 claims 4
- 125000000547 substituted alkyl group Chemical group 0.000 claims 4
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 claims 3
- AMFYRKOUWBAGHV-UHFFFAOYSA-N 1h-pyrazolo[4,3-b]pyridine Chemical compound C1=CN=C2C=NNC2=C1 AMFYRKOUWBAGHV-UHFFFAOYSA-N 0.000 claims 3
- GAMYYCRTACQSBR-UHFFFAOYSA-N 4-azabenzimidazole Chemical compound C1=CC=C2NC=NC2=N1 GAMYYCRTACQSBR-UHFFFAOYSA-N 0.000 claims 3
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 3
- 208000004736 B-Cell Leukemia Diseases 0.000 claims 3
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 3
- 208000003950 B-cell lymphoma Diseases 0.000 claims 3
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 3
- 125000004650 C1-C8 alkynyl group Chemical group 0.000 claims 3
- 206010009944 Colon cancer Diseases 0.000 claims 3
- 206010018338 Glioma Diseases 0.000 claims 3
- 208000017604 Hodgkin disease Diseases 0.000 claims 3
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims 3
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 3
- 208000006404 Large Granular Lymphocytic Leukemia Diseases 0.000 claims 3
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims 3
- 208000034578 Multiple myelomas Diseases 0.000 claims 3
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 3
- 150000001204 N-oxides Chemical class 0.000 claims 3
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 3
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 claims 3
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 3
- 208000033759 Prolymphocytic T-Cell Leukemia Diseases 0.000 claims 3
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 claims 3
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 claims 3
- 206010042971 T-cell lymphoma Diseases 0.000 claims 3
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 claims 3
- 208000026651 T-cell prolymphocytic leukemia Diseases 0.000 claims 3
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 claims 3
- 208000017733 acquired polycythemia vera Diseases 0.000 claims 3
- 208000036677 acute biphenotypic leukemia Diseases 0.000 claims 3
- 230000001154 acute effect Effects 0.000 claims 3
- 208000015230 aggressive NK-cell leukemia Diseases 0.000 claims 3
- RFRXIWQYSOIBDI-UHFFFAOYSA-N benzarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC=C(O)C=C1 RFRXIWQYSOIBDI-UHFFFAOYSA-N 0.000 claims 3
- OGEBRHQLRGFBNV-RZDIXWSQSA-N chembl2036808 Chemical compound C12=NC(NCCCC)=NC=C2C(C=2C=CC(F)=CC=2)=NN1C[C@H]1CC[C@H](N)CC1 OGEBRHQLRGFBNV-RZDIXWSQSA-N 0.000 claims 3
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 claims 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 3
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 claims 3
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 claims 3
- ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 claims 3
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 claims 3
- 125000000842 isoxazolyl group Chemical group 0.000 claims 3
- 208000032839 leukemia Diseases 0.000 claims 3
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 claims 3
- LVWZTYCIRDMTEY-UHFFFAOYSA-N metamizole Chemical compound O=C1C(N(CS(O)(=O)=O)C)=C(C)N(C)N1C1=CC=CC=C1 LVWZTYCIRDMTEY-UHFFFAOYSA-N 0.000 claims 3
- 125000006578 monocyclic heterocycloalkyl group Chemical group 0.000 claims 3
- 208000010626 plasma cell neoplasm Diseases 0.000 claims 3
- 208000037244 polycythemia vera Diseases 0.000 claims 3
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 claims 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 239000012453 solvate Substances 0.000 claims 3
- VLLMWSRANPNYQX-UHFFFAOYSA-N thiadiazole Chemical compound C1=CSN=N1.C1=CSN=N1 VLLMWSRANPNYQX-UHFFFAOYSA-N 0.000 claims 3
- 229930192474 thiophene Natural products 0.000 claims 3
- OVCXRBARSPBVMC-UHFFFAOYSA-N triazolopyridine Chemical compound C=1N2C(C(C)C)=NN=C2C=CC=1C=1OC=NC=1C1=CC=C(F)C=C1 OVCXRBARSPBVMC-UHFFFAOYSA-N 0.000 claims 3
- VJSIXUQLTJCRCS-DFQXCPINSA-N (2s)-2-[2-[[(4r)-4-carboxy-4-[[(3r)-3,4-dicarboxy-3-hydroxybutanoyl]amino]butyl]amino]-2-oxoethyl]-2-hydroxybutanedioic acid Chemical compound OC(=O)C[C@](O)(C(O)=O)CC(=O)NCCC[C@H](C(O)=O)NC(=O)C[C@](O)(C(O)=O)CC(O)=O VJSIXUQLTJCRCS-DFQXCPINSA-N 0.000 claims 2
- FTNJQNQLEGKTGD-UHFFFAOYSA-N 1,3-benzodioxole Chemical compound C1=CC=C2OCOC2=C1 FTNJQNQLEGKTGD-UHFFFAOYSA-N 0.000 claims 2
- 206010073360 Appendix cancer Diseases 0.000 claims 2
- 206010003571 Astrocytoma Diseases 0.000 claims 2
- 206010005949 Bone cancer Diseases 0.000 claims 2
- 208000018084 Bone neoplasm Diseases 0.000 claims 2
- 206010014967 Ependymoma Diseases 0.000 claims 2
- 208000006168 Ewing Sarcoma Diseases 0.000 claims 2
- 206010051066 Gastrointestinal stromal tumour Diseases 0.000 claims 2
- 208000009164 Islet Cell Adenoma Diseases 0.000 claims 2
- 206010023825 Laryngeal cancer Diseases 0.000 claims 2
- 208000006644 Malignant Fibrous Histiocytoma Diseases 0.000 claims 2
- 206010073059 Malignant neoplasm of unknown primary site Diseases 0.000 claims 2
- 208000003445 Mouth Neoplasms Diseases 0.000 claims 2
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 2
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 claims 2
- 206010061306 Nasopharyngeal cancer Diseases 0.000 claims 2
- 208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 claims 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 2
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims 2
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 2
- 201000000582 Retinoblastoma Diseases 0.000 claims 2
- 206010039491 Sarcoma Diseases 0.000 claims 2
- 208000021712 Soft tissue sarcoma Diseases 0.000 claims 2
- 208000015778 Undifferentiated pleomorphic sarcoma Diseases 0.000 claims 2
- 208000021780 appendiceal neoplasm Diseases 0.000 claims 2
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 2
- 230000006369 cell cycle progression Effects 0.000 claims 2
- 230000002490 cerebral effect Effects 0.000 claims 2
- 208000006990 cholangiocarcinoma Diseases 0.000 claims 2
- 210000001072 colon Anatomy 0.000 claims 2
- 208000029742 colonic neoplasm Diseases 0.000 claims 2
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 claims 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 2
- 230000002496 gastric effect Effects 0.000 claims 2
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 claims 2
- 208000003884 gestational trophoblastic disease Diseases 0.000 claims 2
- 201000010536 head and neck cancer Diseases 0.000 claims 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims 2
- 125000005945 imidazopyridyl group Chemical group 0.000 claims 2
- 230000001939 inductive effect Effects 0.000 claims 2
- 206010023841 laryngeal neoplasm Diseases 0.000 claims 2
- 210000004185 liver Anatomy 0.000 claims 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 2
- SFTZRUZMNGBFFL-UHFFFAOYSA-N methyl 4-(3-fluorophenyl)-5-methyl-2-[5-propan-2-ylsulfanyl-4-[4-(trifluoromethyl)cyclohexen-1-yl]-1,3-thiazol-2-yl]pyrazole-3-carboxylate Chemical compound FC=1C=C(C=CC=1)C=1C(=NN(C=1C(=O)OC)C=1SC(=C(N=1)C1=CCC(CC1)C(F)(F)F)SC(C)C)C SFTZRUZMNGBFFL-UHFFFAOYSA-N 0.000 claims 2
- 125000002950 monocyclic group Chemical group 0.000 claims 2
- 125000002757 morpholinyl group Chemical group 0.000 claims 2
- 201000006462 myelodysplastic/myeloproliferative neoplasm Diseases 0.000 claims 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 2
- 201000008968 osteosarcoma Diseases 0.000 claims 2
- 201000002528 pancreatic cancer Diseases 0.000 claims 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 2
- 208000022102 pancreatic neuroendocrine neoplasm Diseases 0.000 claims 2
- 208000021010 pancreatic neuroendocrine tumor Diseases 0.000 claims 2
- 125000004193 piperazinyl group Chemical group 0.000 claims 2
- 125000003386 piperidinyl group Chemical group 0.000 claims 2
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 2
- 206010038038 rectal cancer Diseases 0.000 claims 2
- 201000001275 rectum cancer Diseases 0.000 claims 2
- 229920006395 saturated elastomer Polymers 0.000 claims 2
- 201000002314 small intestine cancer Diseases 0.000 claims 2
- 210000002784 stomach Anatomy 0.000 claims 2
- 208000008732 thymoma Diseases 0.000 claims 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 1
- HEMIXKBRKYHBND-UHFFFAOYSA-N 2-[4,5-bis(4-methoxyphenyl)-1,3-thiazol-2-yl]-4-(3-fluorophenyl)-5-methylpyrazole-3-carboxylic acid Chemical compound COC1=CC=C(C=C1)C=1N=C(SC=1C1=CC=C(C=C1)OC)N1N=C(C(=C1C(=O)O)C1=CC(=CC=C1)F)C HEMIXKBRKYHBND-UHFFFAOYSA-N 0.000 claims 1
- KLXJYYCBHROYPO-UHFFFAOYSA-N 2-[4,5-bis[4-(trifluoromethyl)phenyl]-1,3-thiazol-2-yl]-4-(3-fluorophenyl)-5-methylpyrazole-3-carboxylic acid Chemical compound FC(C1=CC=C(C=C1)C=1N=C(SC=1C1=CC=C(C=C1)C(F)(F)F)N1N=C(C(=C1C(=O)O)C1=CC(=CC=C1)F)C)(F)F KLXJYYCBHROYPO-UHFFFAOYSA-N 0.000 claims 1
- MXACZLIQEYYSHM-UHFFFAOYSA-N 2-[4-(1,4-dioxaspiro[4.5]dec-7-en-8-yl)-5-propan-2-ylsulfanyl-1,3-thiazol-2-yl]-4-(3-fluorophenyl)-5-methylpyrazole-3-carboxylic acid Chemical compound FC=1C=C(C=CC=1)C=1C(=NN(C=1C(=O)O)C=1SC(=C(N=1)C1=CCC2(OCCO2)CC1)SC(C)C)C MXACZLIQEYYSHM-UHFFFAOYSA-N 0.000 claims 1
- WWQFHKYCDFDXOY-UHFFFAOYSA-N 2-[4-(3-fluorophenyl)-3,5-dimethylpyrazol-1-yl]-5-propan-2-ylsulfanyl-4-[4-(trifluoromethyl)phenyl]-1,3-thiazole Chemical compound CC(C)Sc1sc(nc1-c1ccc(cc1)C(F)(F)F)-n1nc(C)c(c1C)-c1cccc(F)c1 WWQFHKYCDFDXOY-UHFFFAOYSA-N 0.000 claims 1
- ARJRMFMVIMXNAJ-UHFFFAOYSA-N 2-[4-(3-fluorophenyl)-3-methylpyrazol-1-yl]-4,5-bis[4-(trifluoromethyl)phenyl]-1,3-thiazole Chemical compound FC=1C=C(C=CC=1)C=1C(=NN(C=1)C=1SC(=C(N=1)C1=CC=C(C=C1)C(F)(F)F)C1=CC=C(C=C1)C(F)(F)F)C ARJRMFMVIMXNAJ-UHFFFAOYSA-N 0.000 claims 1
- QODPSINGCLBNLF-UHFFFAOYSA-N 2-[4-(4,4-difluoropiperidin-1-yl)-5-propan-2-ylsulfanyl-1,3-thiazol-2-yl]-4-(3-fluorophenyl)-5-methylpyrazole-3-carboxylic acid Chemical compound FC1(CCN(CC1)C=1N=C(SC=1SC(C)C)N1N=C(C(=C1C(=O)O)C1=CC(=CC=C1)F)C)F QODPSINGCLBNLF-UHFFFAOYSA-N 0.000 claims 1
- AFTBBPCVOXLMJW-UHFFFAOYSA-N 2-[4-(4,4-dimethylcyclohexen-1-yl)-5-propan-2-ylsulfanyl-1,3-thiazol-2-yl]-4-(3-fluorophenyl)-5-methylpyrazole-3-carboxylic acid Chemical compound CC1(CC=C(CC1)C=1N=C(SC=1SC(C)C)N1N=C(C(=C1C(=O)O)C1=CC(=CC=C1)F)C)C AFTBBPCVOXLMJW-UHFFFAOYSA-N 0.000 claims 1
- OSMVVLIXEOTTAI-UHFFFAOYSA-N 2-[4-(4,4-dimethylpiperidin-1-yl)-5-propan-2-ylsulfanyl-1,3-thiazol-2-yl]-4-(3-fluorophenyl)-5-methylpyrazole-3-carboxylic acid Chemical compound CC1(CCN(CC1)C=1N=C(SC=1SC(C)C)N1N=C(C(=C1C(=O)O)C1=CC(=CC=C1)F)C)C OSMVVLIXEOTTAI-UHFFFAOYSA-N 0.000 claims 1
- VBNPMHGEOJTKAD-UHFFFAOYSA-N 2-[4-(4-acetylpiperazin-1-yl)-5-propan-2-ylsulfanyl-1,3-thiazol-2-yl]-4-(3-fluorophenyl)-5-methylpyrazole-3-carboxylic acid Chemical compound C(C)(=O)N1CCN(CC1)C=1N=C(SC=1SC(C)C)N1N=C(C(=C1C(=O)O)C1=CC(=CC=C1)F)C VBNPMHGEOJTKAD-UHFFFAOYSA-N 0.000 claims 1
- CCNGVHKBAFQHLJ-UHFFFAOYSA-N 2-[4-(4-cyanopiperidin-1-yl)-5-propan-2-ylsulfanyl-1,3-thiazol-2-yl]-4-(3-fluorophenyl)-5-methylpyrazole-3-carboxylic acid Chemical compound C(#N)C1CCN(CC1)C=1N=C(SC=1SC(C)C)N1N=C(C(=C1C(=O)O)C1=CC(=CC=C1)F)C CCNGVHKBAFQHLJ-UHFFFAOYSA-N 0.000 claims 1
- LULUEXOUOGDMHT-UHFFFAOYSA-N 2-[4-(4-cyclopropylpiperazin-1-yl)-5-propan-2-ylsulfanyl-1,3-thiazol-2-yl]-4-(3-fluorophenyl)-5-methylpyrazole-3-carboxylic acid Chemical compound C1(CC1)N1CCN(CC1)C=1N=C(SC=1SC(C)C)N1N=C(C(=C1C(=O)O)C1=CC(=CC=C1)F)C LULUEXOUOGDMHT-UHFFFAOYSA-N 0.000 claims 1
- HZCITNCAZYWLFW-UHFFFAOYSA-N 2-[4-(4-ethylpiperazin-1-yl)-5-propan-2-ylsulfanyl-1,3-thiazol-2-yl]-4-(3-fluorophenyl)-5-methylpyrazole-3-carboxylic acid Chemical compound C(C)N1CCN(CC1)C=1N=C(SC=1SC(C)C)N1N=C(C(=C1C(=O)O)C1=CC(=CC=C1)F)C HZCITNCAZYWLFW-UHFFFAOYSA-N 0.000 claims 1
- MBIXOWVGXJGNGS-UHFFFAOYSA-N 2-[4-(4-tert-butyl-3-oxopiperazin-1-yl)-5-propan-2-ylsulfanyl-1,3-thiazol-2-yl]-4-(3-fluorophenyl)-5-methylpyrazole-3-carboxylic acid Chemical compound C(C)(C)(C)N1C(CN(CC1)C=1N=C(SC=1SC(C)C)N1N=C(C(=C1C(=O)O)C1=CC(=CC=C1)F)C)=O MBIXOWVGXJGNGS-UHFFFAOYSA-N 0.000 claims 1
- NCNGBIQBLGBFMB-UHFFFAOYSA-N 2-[4-(4-tert-butylpiperidin-1-yl)-5-propan-2-ylsulfanyl-1,3-thiazol-2-yl]-4-(3-fluorophenyl)-5-methylpyrazole-3-carboxylic acid Chemical compound C(C)(C)(C)C1CCN(CC1)C=1N=C(SC=1SC(C)C)N1N=C(C(=C1C(=O)O)C1=CC(=CC=C1)F)C NCNGBIQBLGBFMB-UHFFFAOYSA-N 0.000 claims 1
- WIKUALXMWADVNC-UHFFFAOYSA-N 2-[4-(6-azaspiro[2.5]octan-6-yl)-5-propan-2-ylsulfanyl-1,3-thiazol-2-yl]-4-(3-fluorophenyl)-5-methylpyrazole-3-carboxylic acid Chemical compound FC=1C=C(C=CC=1)C=1C(=NN(C=1C(=O)O)C=1SC(=C(N=1)N1CCC2(CC2)CC1)SC(C)C)C WIKUALXMWADVNC-UHFFFAOYSA-N 0.000 claims 1
- KYQAWTUXPJTFKH-UHFFFAOYSA-N 2-[4-[4-chloro-2-(oxetan-3-yloxy)phenyl]-5-propan-2-ylsulfanyl-1,3-thiazol-2-yl]-5-methylpyrazole-3-carboxylic acid Chemical compound ClC1=CC(=C(C=C1)C=1N=C(SC=1SC(C)C)N1N=C(C=C1C(=O)O)C)OC1COC1 KYQAWTUXPJTFKH-UHFFFAOYSA-N 0.000 claims 1
- CGGOKPPVHPSIDS-UHFFFAOYSA-N 2-[4-[4-chloro-3-(morpholine-4-carbonyl)phenyl]-5-propan-2-ylsulfanyl-1,3-thiazol-2-yl]-4-(3-fluorophenyl)-5-methylpyrazole-3-carboxylic acid Chemical compound ClC1=C(C=C(C=C1)C=1N=C(SC=1SC(C)C)N1N=C(C(=C1C(=O)O)C1=CC(=CC=C1)F)C)C(=O)N1CCOCC1 CGGOKPPVHPSIDS-UHFFFAOYSA-N 0.000 claims 1
- RASYQZCHAFQHCZ-UHFFFAOYSA-N 2-[4-[4-chloro-3-(oxetan-3-yloxy)phenyl]-5-propan-2-ylsulfanyl-1,3-thiazol-2-yl]-5-methylpyrazole-3-carboxylic acid Chemical compound ClC1=C(C=C(C=C1)C=1N=C(SC=1SC(C)C)N1N=C(C=C1C(=O)O)C)OC1COC1 RASYQZCHAFQHCZ-UHFFFAOYSA-N 0.000 claims 1
- YTSYITZBAHXPFA-UHFFFAOYSA-N 2-[5-(3,4-dichlorophenyl)-1-(2-methylpropyl)-1,2,4-triazol-3-yl]-4-(3-fluorophenyl)-5-methylpyrazole-3-carboxylic acid Chemical compound ClC=1C=C(C=CC=1Cl)C1=NC(=NN1CC(C)C)N1N=C(C(=C1C(=O)O)C1=CC(=CC=C1)F)C YTSYITZBAHXPFA-UHFFFAOYSA-N 0.000 claims 1
- PZERARTUCDKDRE-UHFFFAOYSA-N 2-[5-(3,4-dichlorophenyl)-2-(2-methylpropyl)-1,2,4-triazol-3-yl]-4-(3-fluorophenyl)-5-methylpyrazole-3-carboxylic acid Chemical compound ClC=1C=C(C=CC=1Cl)C1=NN(C(=N1)N1N=C(C(=C1C(=O)O)C1=CC(=CC=C1)F)C)CC(C)C PZERARTUCDKDRE-UHFFFAOYSA-N 0.000 claims 1
- ILOOJEWVWVLTQT-UHFFFAOYSA-N 2-[5-[4-[2-(2-ethoxyethoxy)ethoxy]phenyl]-4-[4-(trifluoromethyl)phenyl]-1,3-thiazol-2-yl]-4-(3-fluorophenyl)-5-methylpyrazole-3-carboxylic acid Chemical compound C(C)OCCOCCOC1=CC=C(C=C1)C1=C(N=C(S1)N1N=C(C(=C1C(=O)O)C1=CC(=CC=C1)F)C)C1=CC=C(C=C1)C(F)(F)F ILOOJEWVWVLTQT-UHFFFAOYSA-N 0.000 claims 1
- VBGNUHKNSSJROF-UHFFFAOYSA-N 4-(3,4-dichlorophenyl)-2-[4-(2,6-dimethylpyridin-4-yl)-3-methylpyrazol-1-yl]-5-propan-2-ylsulfanyl-1,3-thiazole Chemical compound ClC=1C=C(C=CC=1Cl)C=1N=C(SC=1SC(C)C)N1N=C(C(=C1)C1=CC(=NC(=C1)C)C)C VBGNUHKNSSJROF-UHFFFAOYSA-N 0.000 claims 1
- FGVVCPHMRVSKQO-UHFFFAOYSA-N 4-(3-fluorophenyl)-2-[4-(3-fluorophenyl)-5-[4-(trifluoromethyl)phenyl]-1,3-thiazol-2-yl]-5-methylpyrazole-3-carboxylic acid Chemical compound FC=1C=C(C=CC=1)C=1C(=NN(C=1C(=O)O)C=1SC(=C(N=1)C1=CC(=CC=C1)F)C1=CC=C(C=C1)C(F)(F)F)C FGVVCPHMRVSKQO-UHFFFAOYSA-N 0.000 claims 1
- ZBVZNYYQZRSPRM-UHFFFAOYSA-N 4-(3-fluorophenyl)-2-[4-(4-methoxyphenyl)-5-[4-(trifluoromethyl)phenyl]-1,3-thiazol-2-yl]-5-methylpyrazole-3-carboxylic acid Chemical compound FC=1C=C(C=CC=1)C=1C(=NN(C=1C(=O)O)C=1SC(=C(N=1)C1=CC=C(C=C1)OC)C1=CC=C(C=C1)C(F)(F)F)C ZBVZNYYQZRSPRM-UHFFFAOYSA-N 0.000 claims 1
- LQWKANGGFIUBES-UHFFFAOYSA-N 4-(3-fluorophenyl)-2-[4-[3-methoxy-3-(trifluoromethyl)-8-azabicyclo[3.2.1]octan-8-yl]-5-propan-2-ylsulfanyl-1,3-thiazol-2-yl]-5-methylpyrazole-3-carboxylic acid Chemical compound FC=1C=C(C=CC=1)C=1C(=NN(C=1C(=O)O)C=1SC(=C(N=1)N1C2CC(CC1CC2)(C(F)(F)F)OC)SC(C)C)C LQWKANGGFIUBES-UHFFFAOYSA-N 0.000 claims 1
- FAVQFPULQZOYNO-UHFFFAOYSA-N 4-(3-fluorophenyl)-2-[4-[4-(2-methoxyethoxy)-4-(trifluoromethyl)piperidin-1-yl]-5-propan-2-ylsulfanyl-1,3-thiazol-2-yl]-5-methylpyrazole-3-carboxylic acid Chemical compound FC=1C=C(C=CC=1)C=1C(=NN(C=1C(=O)O)C=1SC(=C(N=1)N1CCC(CC1)(C(F)(F)F)OCCOC)SC(C)C)C FAVQFPULQZOYNO-UHFFFAOYSA-N 0.000 claims 1
- AWPZZTBRRNIBJH-UHFFFAOYSA-N 4-(3-fluorophenyl)-2-[4-[4-methoxy-4-(trifluoromethyl)piperidin-1-yl]-5-propan-2-ylsulfanyl-1,3-thiazol-2-yl]-5-methylpyrazole-3-carboxylic acid Chemical compound FC=1C=C(C=CC=1)C=1C(=NN(C=1C(=O)O)C=1SC(=C(N=1)N1CCC(CC1)(C(F)(F)F)OC)SC(C)C)C AWPZZTBRRNIBJH-UHFFFAOYSA-N 0.000 claims 1
- MOJWDINGMVNHPX-UHFFFAOYSA-N 4-(3-fluorophenyl)-2-[5-(1-hydroxyethyl)-4-[4-(trifluoromethyl)phenyl]-1,3-thiazol-2-yl]-5-methylpyrazole-3-carboxylic acid Chemical compound FC=1C=C(C=CC=1)C=1C(=NN(C=1C(=O)O)C=1SC(=C(N=1)C1=CC=C(C=C1)C(F)(F)F)C(C)O)C MOJWDINGMVNHPX-UHFFFAOYSA-N 0.000 claims 1
- IRFGSCOKPCDOAM-UHFFFAOYSA-N 4-(3-fluorophenyl)-2-[5-(1-methoxyethyl)-4-[4-(trifluoromethyl)phenyl]-1,3-thiazol-2-yl]-5-methylpyrazole-3-carboxylic acid Chemical compound FC=1C=C(C=CC=1)C=1C(=NN(C=1C(=O)O)C=1SC(=C(N=1)C1=CC=C(C=C1)C(F)(F)F)C(C)OC)C IRFGSCOKPCDOAM-UHFFFAOYSA-N 0.000 claims 1
- OTVZZJAIAXAJJW-UHFFFAOYSA-N 4-(3-fluorophenyl)-2-[5-(2-hydroxyethyl)-4-[4-(trifluoromethyl)phenyl]-1,3-thiazol-2-yl]-5-methylpyrazole-3-carboxylic acid Chemical compound FC=1C=C(C=CC=1)C=1C(=NN(C=1C(=O)O)C=1SC(=C(N=1)C1=CC=C(C=C1)C(F)(F)F)CCO)C OTVZZJAIAXAJJW-UHFFFAOYSA-N 0.000 claims 1
- YDRDXVSBBVJBHG-UHFFFAOYSA-N 4-(3-fluorophenyl)-2-[5-(3-fluorophenyl)-4-[4-(trifluoromethyl)phenyl]-1,3-thiazol-2-yl]-5-methylpyrazole-3-carboxylic acid Chemical compound FC=1C=C(C=CC=1)C=1C(=NN(C=1C(=O)O)C=1SC(=C(N=1)C1=CC=C(C=C1)C(F)(F)F)C1=CC(=CC=C1)F)C YDRDXVSBBVJBHG-UHFFFAOYSA-N 0.000 claims 1
- CYRQULRVUOCILV-UHFFFAOYSA-N 4-(3-fluorophenyl)-2-[5-(4-methoxyphenyl)-4-[4-(trifluoromethyl)phenyl]-1,3-thiazol-2-yl]-5-methylpyrazole-3-carboxylic acid Chemical compound FC=1C=C(C=CC=1)C=1C(=NN(C=1C(=O)O)C=1SC(=C(N=1)C1=CC=C(C=C1)C(F)(F)F)C1=CC=C(C=C1)OC)C CYRQULRVUOCILV-UHFFFAOYSA-N 0.000 claims 1
- YPLCMRXNEOKHGI-UHFFFAOYSA-N 4-(3-fluorophenyl)-2-[5-(hydroxymethyl)-4-[4-(trifluoromethyl)phenyl]-1,3-thiazol-2-yl]-5-methylpyrazole-3-carboxylic acid Chemical compound FC=1C=C(C=CC=1)C=1C(=NN(C=1C(=O)O)C=1SC(=C(N=1)C1=CC=C(C=C1)C(F)(F)F)CO)C YPLCMRXNEOKHGI-UHFFFAOYSA-N 0.000 claims 1
- PYXQFFSDMQRZKG-UHFFFAOYSA-N 4-(3-fluorophenyl)-2-[5-(methoxymethyl)-4-[4-(trifluoromethyl)phenyl]-1,3-thiazol-2-yl]-5-methylpyrazole-3-carboxylic acid Chemical compound FC=1C=C(C=CC=1)C=1C(=NN(C=1C(=O)O)C=1SC(=C(N=1)C1=CC=C(C=C1)C(F)(F)F)COC)C PYXQFFSDMQRZKG-UHFFFAOYSA-N 0.000 claims 1
- ANQVCHHDHFBBAZ-UHFFFAOYSA-N 4-(3-fluorophenyl)-2-[5-[2-methoxyethyl(methyl)amino]-4-[4-(trifluoromethyl)phenyl]-1,3-thiazol-2-yl]-5-methylpyrazole-3-carboxylic acid Chemical compound FC=1C=C(C=CC=1)C=1C(=NN(C=1C(=O)O)C=1SC(=C(N=1)C1=CC=C(C=C1)C(F)(F)F)N(C)CCOC)C ANQVCHHDHFBBAZ-UHFFFAOYSA-N 0.000 claims 1
- GBARCWRQYBYIQH-UHFFFAOYSA-N 4-(3-fluorophenyl)-2-[5-[3-(2-methoxyethylamino)-3-oxopropyl]-4-[4-(trifluoromethyl)phenyl]-1,3-thiazol-2-yl]-5-methylpyrazole-3-carboxylic acid Chemical compound FC=1C=C(C=CC=1)C=1C(=NN(C=1C(=O)O)C=1SC(=C(N=1)C1=CC=C(C=C1)C(F)(F)F)CCC(=O)NCCOC)C GBARCWRQYBYIQH-UHFFFAOYSA-N 0.000 claims 1
- MNIOJZUXIPAEPG-UHFFFAOYSA-N 4-(3-fluorophenyl)-2-[5-[3-[2-methoxyethyl(methyl)amino]-3-oxopropyl]-4-[4-(trifluoromethyl)phenyl]-1,3-thiazol-2-yl]-5-methylpyrazole-3-carboxylic acid Chemical compound FC=1C=C(C=CC=1)C=1C(=NN(C=1C(=O)O)C=1SC(=C(N=1)C1=CC=C(C=C1)C(F)(F)F)CCC(=O)N(C)CCOC)C MNIOJZUXIPAEPG-UHFFFAOYSA-N 0.000 claims 1
- ZKDVPTRNSAKTNV-UHFFFAOYSA-N 4-(3-fluorophenyl)-2-[5-[4-(2-methoxyethoxy)phenyl]-4-[4-(trifluoromethyl)phenyl]-1,3-thiazol-2-yl]-5-methylpyrazole-3-carboxylic acid Chemical compound FC=1C=C(C=CC=1)C=1C(=NN(C=1C(=O)O)C=1SC(=C(N=1)C1=CC=C(C=C1)C(F)(F)F)C1=CC=C(C=C1)OCCOC)C ZKDVPTRNSAKTNV-UHFFFAOYSA-N 0.000 claims 1
- VSFQPUPWARSYMC-UHFFFAOYSA-N 4-(3-fluorophenyl)-2-[5-[4-(2-methoxyethylcarbamoyl)phenyl]-4-[4-(trifluoromethyl)phenyl]-1,3-thiazol-2-yl]-5-methylpyrazole-3-carboxylic acid Chemical compound FC=1C=C(C=CC=1)C=1C(=NN(C=1C(=O)O)C=1SC(=C(N=1)C1=CC=C(C=C1)C(F)(F)F)C1=CC=C(C=C1)C(NCCOC)=O)C VSFQPUPWARSYMC-UHFFFAOYSA-N 0.000 claims 1
- ZAOLQUZTLMMBIX-UHFFFAOYSA-N 4-(3-fluorophenyl)-2-[5-[4-[(2-methoxyacetyl)-methylamino]phenyl]-4-[4-(trifluoromethyl)phenyl]-1,3-thiazol-2-yl]-5-methylpyrazole-3-carboxylic acid Chemical compound FC=1C=C(C=CC=1)C=1C(=NN(C=1C(=O)O)C=1SC(=C(N=1)C1=CC=C(C=C1)C(F)(F)F)C1=CC=C(C=C1)N(C(COC)=O)C)C ZAOLQUZTLMMBIX-UHFFFAOYSA-N 0.000 claims 1
- GCIORPXAHQQNCT-UHFFFAOYSA-N 4-(3-fluorophenyl)-2-[5-[4-[(2-methoxyacetyl)amino]phenyl]-4-[4-(trifluoromethyl)phenyl]-1,3-thiazol-2-yl]-5-methylpyrazole-3-carboxylic acid Chemical compound FC=1C=C(C=CC=1)C=1C(=NN(C=1C(=O)O)C=1SC(=C(N=1)C1=CC=C(C=C1)C(F)(F)F)C1=CC=C(C=C1)NC(COC)=O)C GCIORPXAHQQNCT-UHFFFAOYSA-N 0.000 claims 1
- HDFPPXRPFDGKMA-UHFFFAOYSA-N 4-(3-fluorophenyl)-2-[5-[4-[2-methoxyethyl(methyl)carbamoyl]phenyl]-4-[4-(trifluoromethyl)phenyl]-1,3-thiazol-2-yl]-5-methylpyrazole-3-carboxylic acid Chemical compound FC=1C=C(C=CC=1)C=1C(=NN(C=1C(=O)O)C=1SC(=C(N=1)C1=CC=C(C=C1)C(F)(F)F)C1=CC=C(C=C1)C(N(C)CCOC)=O)C HDFPPXRPFDGKMA-UHFFFAOYSA-N 0.000 claims 1
- XWDVJXSJJDSZJE-UHFFFAOYSA-N 4-(3-fluorophenyl)-2-[5-[4-[[2-(2-methoxyethoxy)acetyl]-methylamino]phenyl]-4-[4-(trifluoromethyl)phenyl]-1,3-thiazol-2-yl]-5-methylpyrazole-3-carboxylic acid Chemical compound FC=1C=C(C=CC=1)C=1C(=NN(C=1C(=O)O)C=1SC(=C(N=1)C1=CC=C(C=C1)C(F)(F)F)C1=CC=C(C=C1)N(C(COCCOC)=O)C)C XWDVJXSJJDSZJE-UHFFFAOYSA-N 0.000 claims 1
- PKEAENJRMIHJDF-UHFFFAOYSA-N 4-(3-fluorophenyl)-2-[5-[4-[[2-(2-methoxyethoxy)acetyl]amino]phenyl]-4-[4-(trifluoromethyl)phenyl]-1,3-thiazol-2-yl]-5-methylpyrazole-3-carboxylic acid Chemical compound FC=1C=C(C=CC=1)C=1C(=NN(C=1C(=O)O)C=1SC(=C(N=1)C1=CC=C(C=C1)C(F)(F)F)C1=CC=C(C=C1)NC(COCCOC)=O)C PKEAENJRMIHJDF-UHFFFAOYSA-N 0.000 claims 1
- SVGCXHNDQRLAOX-UHFFFAOYSA-N 4-(3-fluorophenyl)-5-methyl-2-(4-morpholin-4-yl-5-propan-2-ylsulfanyl-1,3-thiazol-2-yl)pyrazole-3-carboxylic acid Chemical compound FC=1C=C(C=CC=1)C=1C(=NN(C=1C(=O)O)C=1SC(=C(N=1)N1CCOCC1)SC(C)C)C SVGCXHNDQRLAOX-UHFFFAOYSA-N 0.000 claims 1
- VSEJDOCSAASISS-UHFFFAOYSA-N 4-(3-fluorophenyl)-5-methyl-2-(4-piperazin-1-yl-5-propan-2-ylsulfanyl-1,3-thiazol-2-yl)pyrazole-3-carboxylic acid Chemical compound FC=1C=C(C=CC=1)C=1C(=NN(C=1C(=O)O)C=1SC(=C(N=1)N1CCNCC1)SC(C)C)C VSEJDOCSAASISS-UHFFFAOYSA-N 0.000 claims 1
- GOUOYBYVARLAMY-UHFFFAOYSA-N 4-(3-fluorophenyl)-5-methyl-2-(4-piperidin-1-yl-5-propan-2-ylsulfanyl-1,3-thiazol-2-yl)pyrazole-3-carboxylic acid Chemical compound FC=1C=C(C=CC=1)C=1C(=NN(C=1C(=O)O)C=1SC(=C(N=1)N1CCCCC1)SC(C)C)C GOUOYBYVARLAMY-UHFFFAOYSA-N 0.000 claims 1
- MZRSBBMZOWCXQT-UHFFFAOYSA-N 4-(3-fluorophenyl)-5-methyl-2-[4-(2-methylprop-1-enyl)-5-[4-(trifluoromethyl)phenyl]-1,3-thiazol-2-yl]pyrazole-3-carboxylic acid Chemical compound FC=1C=C(C=CC=1)C=1C(=NN(C=1C(=O)O)C=1SC(=C(N=1)C=C(C)C)C1=CC=C(C=C1)C(F)(F)F)C MZRSBBMZOWCXQT-UHFFFAOYSA-N 0.000 claims 1
- PSXGJOOHDPCVMB-UHFFFAOYSA-N 4-(3-fluorophenyl)-5-methyl-2-[4-(4-methylcyclohexen-1-yl)-5-propan-2-ylsulfanyl-1,3-thiazol-2-yl]pyrazole-3-carboxylic acid Chemical compound FC=1C=C(C=CC=1)C=1C(=NN(C=1C(=O)O)C=1SC(=C(N=1)C1=CCC(CC1)C)SC(C)C)C PSXGJOOHDPCVMB-UHFFFAOYSA-N 0.000 claims 1
- AMWBBRHGFYJMIU-UHFFFAOYSA-N 4-(3-fluorophenyl)-5-methyl-2-[4-(4-methylpiperazin-1-yl)-5-propan-2-ylsulfanyl-1,3-thiazol-2-yl]pyrazole-3-carboxylic acid Chemical compound CC(C)Sc1sc(nc1N1CCN(C)CC1)-n1nc(C)c(c1C(O)=O)-c1cccc(F)c1 AMWBBRHGFYJMIU-UHFFFAOYSA-N 0.000 claims 1
- DWCDBJXJFRDDGK-UHFFFAOYSA-N 4-(3-fluorophenyl)-5-methyl-2-[4-(4-methylpiperidin-1-yl)-5-propan-2-ylsulfanyl-1,3-thiazol-2-yl]pyrazole-3-carboxylic acid Chemical compound FC=1C=C(C=CC=1)C=1C(=NN(C=1C(=O)O)C=1SC(=C(N=1)N1CCC(CC1)C)SC(C)C)C DWCDBJXJFRDDGK-UHFFFAOYSA-N 0.000 claims 1
- MEXZXVXRHYRETJ-UHFFFAOYSA-N 4-(3-fluorophenyl)-5-methyl-2-[4-(4-propan-2-ylpiperidin-1-yl)-5-propan-2-ylsulfanyl-1,3-thiazol-2-yl]pyrazole-3-carboxylic acid Chemical compound FC=1C=C(C=CC=1)C=1C(=NN(C=1C(=O)O)C=1SC(=C(N=1)N1CCC(CC1)C(C)C)SC(C)C)C MEXZXVXRHYRETJ-UHFFFAOYSA-N 0.000 claims 1
- DHWNEVSOEHIBKO-UHFFFAOYSA-N 4-(3-fluorophenyl)-5-methyl-2-[4-[4-(5-methyl-1,3,4-oxadiazol-2-yl)phenyl]-5-propan-2-ylsulfanyl-1,3-thiazol-2-yl]pyrazole-3-carboxylic acid Chemical compound FC=1C=C(C=CC=1)C=1C(=NN(C=1C(=O)O)C=1SC(=C(N=1)C1=CC=C(C=C1)C=1OC(=NN=1)C)SC(C)C)C DHWNEVSOEHIBKO-UHFFFAOYSA-N 0.000 claims 1
- MZHXONXWLYFZHN-UHFFFAOYSA-N 4-(3-fluorophenyl)-5-methyl-2-[4-[4-(trifluoromethyl)cyclohexyl]-1,3-thiazol-2-yl]pyrazole-3-carboxylic acid Chemical compound FC=1C=C(C=CC=1)C=1C(=NN(C=1C(=O)O)C=1SC=C(N=1)C1CCC(CC1)C(F)(F)F)C MZHXONXWLYFZHN-UHFFFAOYSA-N 0.000 claims 1
- AFXZTDNOAFVTCB-UHFFFAOYSA-N 4-(3-fluorophenyl)-5-methyl-2-[4-[4-[(2-methylpropan-2-yl)oxycarbonyl]piperazin-1-yl]-5-propan-2-ylsulfanyl-1,3-thiazol-2-yl]pyrazole-3-carboxylic acid Chemical compound C(C)(C)(C)OC(=O)N1CCN(CC1)C=1N=C(SC=1SC(C)C)N1N=C(C(=C1C(=O)O)C1=CC(=CC=C1)F)C AFXZTDNOAFVTCB-UHFFFAOYSA-N 0.000 claims 1
- LVOHTWJMSFETDK-UHFFFAOYSA-N 4-(3-fluorophenyl)-5-methyl-2-[5-(2-methylprop-1-enyl)-4-[4-(trifluoromethyl)phenyl]-1,3-thiazol-2-yl]pyrazole-3-carboxylic acid Chemical compound FC=1C=C(C=CC=1)C=1C(=NN(C=1C(=O)O)C=1SC(=C(N=1)C1=CC=C(C=C1)C(F)(F)F)C=C(C)C)C LVOHTWJMSFETDK-UHFFFAOYSA-N 0.000 claims 1
- MONMQFMKVVUITN-UHFFFAOYSA-N 4-(3-fluorophenyl)-5-methyl-2-[5-(2-methylpropyl)-4-[4-(trifluoromethyl)phenyl]-1,3-thiazol-2-yl]pyrazole-3-carboxylic acid Chemical compound FC=1C=C(C=CC=1)C=1C(=NN(C=1C(=O)O)C=1SC(=C(N=1)C1=CC=C(C=C1)C(F)(F)F)CC(C)C)C MONMQFMKVVUITN-UHFFFAOYSA-N 0.000 claims 1
- FXTNMWFVZPMLIY-UHFFFAOYSA-N 4-(3-fluorophenyl)-5-methyl-2-[5-[3-(methylamino)-3-oxopropyl]-4-[4-(trifluoromethyl)phenyl]-1,3-thiazol-2-yl]pyrazole-3-carboxylic acid Chemical compound FC=1C=C(C=CC=1)C=1C(=NN(C=1C(=O)O)C=1SC(=C(N=1)C1=CC=C(C=C1)C(F)(F)F)CCC(=O)NC)C FXTNMWFVZPMLIY-UHFFFAOYSA-N 0.000 claims 1
- KVDGLCNQBDTZEO-UHFFFAOYSA-N 4-(3-fluorophenyl)-5-methyl-2-[5-[4-(trifluoromethyl)phenyl]-1,3,4-thiadiazol-2-yl]pyrazole-3-carboxylic acid Chemical compound FC=1C=C(C=CC=1)C=1C(=NN(C=1C(=O)O)C=1SC(=NN=1)C1=CC=C(C=C1)C(F)(F)F)C KVDGLCNQBDTZEO-UHFFFAOYSA-N 0.000 claims 1
- JPWBXESEDHCIAY-UHFFFAOYSA-N 4-(3-fluorophenyl)-5-methyl-2-[5-[4-(trifluoromethyl)phenyl]-4-[4-(trifluoromethyl)piperidin-1-yl]-1,3-thiazol-2-yl]pyrazole-3-carboxylic acid Chemical compound FC=1C=C(C=CC=1)C=1C(=NN(C=1C(=O)O)C=1SC(=C(N=1)N1CCC(CC1)C(F)(F)F)C1=CC=C(C=C1)C(F)(F)F)C JPWBXESEDHCIAY-UHFFFAOYSA-N 0.000 claims 1
- UFKOWJPTINPQAR-UHFFFAOYSA-N 4-(3-fluorophenyl)-5-methyl-2-[5-propan-2-ylsulfanyl-4-[3-(trifluoromethyl)pyrrolidin-1-yl]-1,3-thiazol-2-yl]pyrazole-3-carboxylic acid Chemical compound FC=1C=C(C=CC=1)C=1C(=NN(C=1C(=O)O)C=1SC(=C(N=1)N1CC(CC1)C(F)(F)F)SC(C)C)C UFKOWJPTINPQAR-UHFFFAOYSA-N 0.000 claims 1
- PCVWVTWFHYOGQE-UHFFFAOYSA-N 4-(3-fluorophenyl)-5-methyl-2-[5-propan-2-ylsulfanyl-4-[4-(2,2,2-trifluoroethyl)piperazin-1-yl]-1,3-thiazol-2-yl]pyrazole-3-carboxylic acid Chemical compound FC=1C=C(C=CC=1)C=1C(=NN(C=1C(=O)O)C=1SC(=C(N=1)N1CCN(CC1)CC(F)(F)F)SC(C)C)C PCVWVTWFHYOGQE-UHFFFAOYSA-N 0.000 claims 1
- LDSVVHIOWFIJNE-UHFFFAOYSA-N 4-(3-fluorophenyl)-5-methyl-2-[5-propan-2-ylsulfanyl-4-[4-(trifluoromethyl)cyclohexen-1-yl]-1,3-thiazol-2-yl]pyrazole-3-carboxylic acid Chemical compound FC=1C=C(C=CC=1)C=1C(=NN(C=1C(=O)O)C=1SC(=C(N=1)C1=CCC(CC1)C(F)(F)F)SC(C)C)C LDSVVHIOWFIJNE-UHFFFAOYSA-N 0.000 claims 1
- WNJBPYQHSXQXDW-UHFFFAOYSA-N 4-(3-fluorophenyl)-5-methyl-2-[5-propan-2-ylsulfanyl-4-[4-(trifluoromethyl)piperidin-1-yl]-1,3-thiazol-2-yl]pyrazole-3-carboxylic acid Chemical compound FC=1C=C(C=CC=1)C=1C(=NN(C=1C(=O)O)C=1SC(=C(N=1)N1CCC(CC1)C(F)(F)F)SC(C)C)C WNJBPYQHSXQXDW-UHFFFAOYSA-N 0.000 claims 1
- BIFUPFDVXPCIJM-UHFFFAOYSA-N 4-(3-fluorophenyl)-5-oxo-2-[5-propan-2-ylsulfanyl-4-[4-(trifluoromethyl)phenyl]-1,3-thiazol-2-yl]-1H-pyrazole-3-carboxylic acid Chemical compound FC=1C=C(C=CC=1)C=1C(=NN(C=1C(=O)O)C=1SC(=C(N=1)C1=CC=C(C=C1)C(F)(F)F)SC(C)C)O BIFUPFDVXPCIJM-UHFFFAOYSA-N 0.000 claims 1
- 208000030507 AIDS Diseases 0.000 claims 1
- 208000002008 AIDS-Related Lymphoma Diseases 0.000 claims 1
- 208000006468 Adrenal Cortex Neoplasms Diseases 0.000 claims 1
- 206010061424 Anal cancer Diseases 0.000 claims 1
- 208000007860 Anus Neoplasms Diseases 0.000 claims 1
- 206010060971 Astrocytoma malignant Diseases 0.000 claims 1
- 201000008271 Atypical teratoid rhabdoid tumor Diseases 0.000 claims 1
- 206010004146 Basal cell carcinoma Diseases 0.000 claims 1
- 206010004593 Bile duct cancer Diseases 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010006143 Brain stem glioma Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 claims 1
- 206010007279 Carcinoid tumour of the gastrointestinal tract Diseases 0.000 claims 1
- 201000009030 Carcinoma Diseases 0.000 claims 1
- 206010007953 Central nervous system lymphoma Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 1
- 208000005243 Chondrosarcoma Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 208000009798 Craniopharyngioma Diseases 0.000 claims 1
- 208000008743 Desmoplastic Small Round Cell Tumor Diseases 0.000 claims 1
- 206010064581 Desmoplastic small round cell tumour Diseases 0.000 claims 1
- 206010014733 Endometrial cancer Diseases 0.000 claims 1
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 208000017259 Extragonadal germ cell tumor Diseases 0.000 claims 1
- 201000001342 Fallopian tube cancer Diseases 0.000 claims 1
- 208000013452 Fallopian tube neoplasm Diseases 0.000 claims 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 1
- 230000035519 G0 Phase Effects 0.000 claims 1
- 230000010190 G1 phase Effects 0.000 claims 1
- 208000022072 Gallbladder Neoplasms Diseases 0.000 claims 1
- 208000021309 Germ cell tumor Diseases 0.000 claims 1
- 208000032612 Glial tumor Diseases 0.000 claims 1
- 201000010915 Glioblastoma multiforme Diseases 0.000 claims 1
- 208000002125 Hemangioendothelioma Diseases 0.000 claims 1
- 206010021042 Hypopharyngeal cancer Diseases 0.000 claims 1
- 206010056305 Hypopharyngeal neoplasm Diseases 0.000 claims 1
- 206010061252 Intraocular melanoma Diseases 0.000 claims 1
- 208000007766 Kaposi sarcoma Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 201000005099 Langerhans cell histiocytosis Diseases 0.000 claims 1
- 206010023849 Laryngeal papilloma Diseases 0.000 claims 1
- 206010061523 Lip and/or oral cavity cancer Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010025312 Lymphoma AIDS related Diseases 0.000 claims 1
- 208000004059 Male Breast Neoplasms Diseases 0.000 claims 1
- 208000032271 Malignant tumor of penis Diseases 0.000 claims 1
- 208000000172 Medulloblastoma Diseases 0.000 claims 1
- 208000002030 Merkel cell carcinoma Diseases 0.000 claims 1
- 206010027406 Mesothelioma Diseases 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 206010029266 Neuroendocrine carcinoma of the skin Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 208000000160 Olfactory Esthesioneuroblastoma Diseases 0.000 claims 1
- 201000010133 Oligodendroglioma Diseases 0.000 claims 1
- 206010031096 Oropharyngeal cancer Diseases 0.000 claims 1
- 206010057444 Oropharyngeal neoplasm Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061332 Paraganglion neoplasm Diseases 0.000 claims 1
- 208000000821 Parathyroid Neoplasms Diseases 0.000 claims 1
- 208000002471 Penile Neoplasms Diseases 0.000 claims 1
- 206010034299 Penile cancer Diseases 0.000 claims 1
- 208000009565 Pharyngeal Neoplasms Diseases 0.000 claims 1
- 206010034811 Pharyngeal cancer Diseases 0.000 claims 1
- 208000007913 Pituitary Neoplasms Diseases 0.000 claims 1
- 201000008199 Pleuropulmonary blastoma Diseases 0.000 claims 1
- 208000026149 Primary peritoneal carcinoma Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 208000004337 Salivary Gland Neoplasms Diseases 0.000 claims 1
- 206010061934 Salivary gland cancer Diseases 0.000 claims 1
- 208000009359 Sezary Syndrome Diseases 0.000 claims 1
- 208000021388 Sezary disease Diseases 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 206010041067 Small cell lung cancer Diseases 0.000 claims 1
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 1
- 206010057644 Testis cancer Diseases 0.000 claims 1
- 206010043515 Throat cancer Diseases 0.000 claims 1
- 201000009365 Thymic carcinoma Diseases 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 206010044407 Transitional cell cancer of the renal pelvis and ureter Diseases 0.000 claims 1
- 206010046431 Urethral cancer Diseases 0.000 claims 1
- 206010046458 Urethral neoplasms Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 1
- 201000005969 Uveal melanoma Diseases 0.000 claims 1
- 206010047741 Vulval cancer Diseases 0.000 claims 1
- 208000004354 Vulvar Neoplasms Diseases 0.000 claims 1
- 208000016025 Waldenstroem macroglobulinemia Diseases 0.000 claims 1
- 208000008383 Wilms tumor Diseases 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 201000002454 adrenal cortex cancer Diseases 0.000 claims 1
- 208000020990 adrenal cortex carcinoma Diseases 0.000 claims 1
- 208000007128 adrenocortical carcinoma Diseases 0.000 claims 1
- 125000004450 alkenylene group Chemical group 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 125000002947 alkylene group Chemical group 0.000 claims 1
- 125000004419 alkynylene group Chemical group 0.000 claims 1
- 201000011165 anus cancer Diseases 0.000 claims 1
- 230000006907 apoptotic process Effects 0.000 claims 1
- 125000002047 benzodioxolyl group Chemical group O1OC(C2=C1C=CC=C2)* 0.000 claims 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims 1
- 125000002619 bicyclic group Chemical group 0.000 claims 1
- 208000026900 bile duct neoplasm Diseases 0.000 claims 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 claims 1
- 208000002458 carcinoid tumor Diseases 0.000 claims 1
- 230000000747 cardiac effect Effects 0.000 claims 1
- 201000007335 cerebellar astrocytoma Diseases 0.000 claims 1
- 208000030239 cerebral astrocytoma Diseases 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 208000011654 childhood malignant neoplasm Diseases 0.000 claims 1
- 239000000460 chlorine Substances 0.000 claims 1
- 229910052801 chlorine Inorganic materials 0.000 claims 1
- 208000017763 cutaneous neuroendocrine carcinoma Diseases 0.000 claims 1
- 231100000433 cytotoxic Toxicity 0.000 claims 1
- 230000001472 cytotoxic effect Effects 0.000 claims 1
- 208000028715 ductal breast carcinoma in situ Diseases 0.000 claims 1
- 208000014616 embryonal neoplasm Diseases 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 208000032099 esthesioneuroblastoma Diseases 0.000 claims 1
- 208000024519 eye neoplasm Diseases 0.000 claims 1
- 239000011737 fluorine Substances 0.000 claims 1
- 229910052731 fluorine Inorganic materials 0.000 claims 1
- 125000002541 furyl group Chemical group 0.000 claims 1
- 201000010175 gallbladder cancer Diseases 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 201000009277 hairy cell leukemia Diseases 0.000 claims 1
- 125000005059 halophenyl group Chemical group 0.000 claims 1
- 208000029824 high grade glioma Diseases 0.000 claims 1
- 201000008298 histiocytosis Diseases 0.000 claims 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims 1
- 201000006866 hypopharynx cancer Diseases 0.000 claims 1
- 230000002267 hypothalamic effect Effects 0.000 claims 1
- 125000002883 imidazolyl group Chemical group 0.000 claims 1
- 125000004857 imidazopyridinyl group Chemical group N1C(=NC2=C1C=CC=N2)* 0.000 claims 1
- 125000001041 indolyl group Chemical group 0.000 claims 1
- 201000008893 intraocular retinoblastoma Diseases 0.000 claims 1
- 125000001786 isothiazolyl group Chemical group 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 210000001821 langerhans cell Anatomy 0.000 claims 1
- 208000009000 laryngeal papillomatosis Diseases 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000026807 lung carcinoid tumor Diseases 0.000 claims 1
- 201000005296 lung carcinoma Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 201000003175 male breast cancer Diseases 0.000 claims 1
- 208000010907 male breast carcinoma Diseases 0.000 claims 1
- 208000030883 malignant astrocytoma Diseases 0.000 claims 1
- 201000011614 malignant glioma Diseases 0.000 claims 1
- 208000025854 malignant tumor of adrenal cortex Diseases 0.000 claims 1
- 208000026045 malignant tumor of parathyroid gland Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 206010027191 meningioma Diseases 0.000 claims 1
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 claims 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims 1
- 206010051747 multiple endocrine neoplasia Diseases 0.000 claims 1
- 125000001624 naphthyl group Chemical group 0.000 claims 1
- 208000018795 nasal cavity and paranasal sinus carcinoma Diseases 0.000 claims 1
- 201000008026 nephroblastoma Diseases 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- 201000008106 ocular cancer Diseases 0.000 claims 1
- 201000002575 ocular melanoma Diseases 0.000 claims 1
- 201000006958 oropharynx cancer Diseases 0.000 claims 1
- 125000002971 oxazolyl group Chemical group 0.000 claims 1
- 208000007312 paraganglioma Diseases 0.000 claims 1
- 208000028591 pheochromocytoma Diseases 0.000 claims 1
- 208000010916 pituitary tumor Diseases 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 208000016800 primary central nervous system lymphoma Diseases 0.000 claims 1
- 125000003373 pyrazinyl group Chemical group 0.000 claims 1
- 125000005494 pyridonyl group Chemical group 0.000 claims 1
- 208000030859 renal pelvis/ureter urothelial carcinoma Diseases 0.000 claims 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 1
- 201000008205 supratentorial primitive neuroectodermal tumor Diseases 0.000 claims 1
- 201000003120 testicular cancer Diseases 0.000 claims 1
- 125000001113 thiadiazolyl group Chemical group 0.000 claims 1
- 125000000335 thiazolyl group Chemical group 0.000 claims 1
- 125000001544 thienyl group Chemical group 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 206010046766 uterine cancer Diseases 0.000 claims 1
- 208000037965 uterine sarcoma Diseases 0.000 claims 1
- 206010046885 vaginal cancer Diseases 0.000 claims 1
- 208000013139 vaginal neoplasm Diseases 0.000 claims 1
- 201000011531 vascular cancer Diseases 0.000 claims 1
- 206010055031 vascular neoplasm Diseases 0.000 claims 1
- 210000000239 visual pathway Anatomy 0.000 claims 1
- 230000004400 visual pathway Effects 0.000 claims 1
- 201000005102 vulva cancer Diseases 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662428271P | 2016-11-30 | 2016-11-30 | |
| US62/428,271 | 2016-11-30 | ||
| PCT/US2017/063774 WO2018102453A1 (en) | 2016-11-30 | 2017-11-29 | Substituted pyrazole compounds and methods of using them for treatment of hyperproliferative diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3081983A1 true CA3081983A1 (en) | 2018-06-07 |
Family
ID=62241871
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3081983A Pending CA3081983A1 (en) | 2016-11-30 | 2017-11-29 | Substituted pyrazole compounds and methods of using them for treatment of hyperproliferative diseases |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US11325903B2 (enExample) |
| EP (1) | EP3548482A4 (enExample) |
| JP (1) | JP7373992B2 (enExample) |
| CN (2) | CN118930533A (enExample) |
| AU (1) | AU2017366901B2 (enExample) |
| BR (1) | BR112019011044A2 (enExample) |
| CA (1) | CA3081983A1 (enExample) |
| IL (1) | IL266930B2 (enExample) |
| MX (1) | MX2019006299A (enExample) |
| NZ (1) | NZ754827A (enExample) |
| WO (1) | WO2018102453A1 (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3458445B1 (en) | 2016-05-18 | 2021-02-17 | Mirati Therapeutics, Inc. | Kras g12c inhibitors |
| AU2017366901B2 (en) * | 2016-11-30 | 2022-09-29 | Bantam Pharmaceutical, Llc | Substituted pyrazole compounds and methods of using them for treatment of hyperproliferative diseases |
| BR112019011035A2 (pt) * | 2016-11-30 | 2019-10-15 | Bantam Pharmaceutical Llc | métodos de uso de compostos pirazol e pirazol substituído e para o tratamento de doenças hiperproliferativas |
| EP3710439B1 (en) | 2017-11-15 | 2023-02-15 | Mirati Therapeutics, Inc. | Kras g12c inhibitors |
| US10647715B2 (en) | 2017-11-15 | 2020-05-12 | Mirati Therapeutics, Inc. | KRas G12C inhibitors |
| EP3790551A4 (en) | 2018-05-07 | 2022-03-09 | Mirati Therapeutics, Inc. | Kras g12c inhibitors |
| WO2019236966A2 (en) | 2018-06-07 | 2019-12-12 | Bantam Pharmaceutical, Llc | Methods of treatment of cancer with substituted pyrrole and pyrazole compounds and diagnosis of cancers susceptible to treatment with substituted pyrrole and pyrazole compounds |
| EP3849536A4 (en) | 2018-09-10 | 2022-06-29 | Mirati Therapeutics, Inc. | Combination therapies |
| EP3849538A4 (en) | 2018-09-10 | 2022-06-29 | Mirati Therapeutics, Inc. | Combination therapies |
| ES3004338T3 (en) | 2018-09-10 | 2025-03-12 | Mirati Therapeutics Inc | Combination therapies |
| WO2020118066A1 (en) | 2018-12-05 | 2020-06-11 | Mirati Therapeutics, Inc. | Combination therapies |
| EP3908283A4 (en) | 2019-01-10 | 2022-10-12 | Mirati Therapeutics, Inc. | KRAS G12C INHIBITORS |
| CA3142196A1 (en) | 2019-05-31 | 2020-12-03 | Bantam Pharmaceutical, Llc | Crystalline polymorphs of a 1-thiazol-2-yl-pyrazole-5-carboxylic acid derivative |
| EP3976605B1 (en) | 2019-05-31 | 2025-08-20 | Bantam Pharmaceutical, LLC | Methods for making thiazolylpyrazole carboxylic acids and intermediates therefor |
| JP7622043B2 (ja) | 2019-08-29 | 2025-01-27 | ミラティ セラピューティクス， インコーポレイテッド | Ｋｒａｓ ｇ１２ｄ阻害剤 |
| CN114761012B (zh) | 2019-09-24 | 2025-03-21 | 米拉蒂治疗股份有限公司 | 组合疗法 |
| IL294048A (en) | 2019-12-20 | 2022-08-01 | Mirati Therapeutics Inc | sos1 inhibitors |
| US20230212164A1 (en) * | 2020-06-02 | 2023-07-06 | Boehringer Ingelheim International Gmbh | Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer |
| KR20230137286A (ko) | 2020-09-11 | 2023-10-04 | 미라티 테라퓨틱스, 인크. | Kras g12c 억제제의 결정 형태 |
| EP4262807A4 (en) | 2020-12-15 | 2025-04-23 | Mirati Therapeutics, Inc. | Azachinazoline pan-KRAS inhibitors |
| US11999753B2 (en) | 2020-12-16 | 2024-06-04 | Mirati Therapeutics, Inc. | Tetrahydropyridopyrimidine pan-KRas inhibitors |
| KR20240128852A (ko) | 2021-12-01 | 2024-08-27 | 베링거 인겔하임 인터내셔날 게엠베하 | 암 치료를 위한 고리형 2-아미노-3-시아노 티오펜 및 유도체 |
| JP2024543976A (ja) * | 2021-12-01 | 2024-11-26 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 癌の処置のための環化２－アミノ－３－シアノチオフェン及び誘導体 |
| CN116678810A (zh) * | 2022-02-23 | 2023-09-01 | 武汉市鼎华双雄生物科技有限责任公司 | 细胞增殖免疫荧光检测试剂盒及其应用 |
| CN117003651B (zh) * | 2023-09-28 | 2024-01-02 | 广东嘉博制药有限公司 | 一种l-肾上腺素的制备方法 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1301968B1 (it) | 1998-07-30 | 2000-07-20 | Zambon Spa | Derivati di eritromicina ad attivita' antibiotica |
| ES2208227T3 (es) | 1999-12-03 | 2004-06-16 | Pfizer Products Inc. | Compuestos de heteroarilfenilpirazol como agentes antiinflamatorios/analgesicos. |
| EP1513534A2 (en) | 2002-04-04 | 2005-03-16 | Cv Therapeutics, Inc. | Compounds for increasing abca-1 expression useful for treating coronary artery disease and atherosclerosis |
| US20060194807A1 (en) * | 2003-04-03 | 2006-08-31 | Cosford Nicholas D P | Di-aryl substituted pyrazole modulators of metabotropic glutamate receptor-5 |
| JP2006523701A (ja) | 2003-04-18 | 2006-10-19 | メルク エンド カムパニー インコーポレーテッド | ナトリウムチャネルブロッカーとしてのビアリール置換チアゾール、オキサゾール、およびイミダゾール |
| WO2007138110A2 (en) | 2006-06-01 | 2007-12-06 | Devgen N.V. | Compounds that interact with ion channels, in particular with ion channels from the kv family |
| WO2008121861A2 (en) | 2007-03-28 | 2008-10-09 | Xenon Pharmaceuticals Inc. | Pyrazole and pyrrole compounds useful in treating iron disorders |
| MX2010001462A (es) | 2007-08-27 | 2010-03-01 | Basf Se | Compuestos de pirazol para controlar plagas de invertebrados. |
| CN102056907B (zh) | 2008-04-04 | 2014-12-31 | 武田药品工业株式会社 | 杂环衍生物及其用途 |
| CA2722733C (en) | 2008-04-28 | 2016-02-23 | Kyorin Pharmaceutical Co., Ltd. | Cyclopentylacrylamide derivative |
| WO2014066304A1 (en) | 2012-10-22 | 2014-05-01 | Egenix, Inc. | Compositions and methods for treating or preventing diseases or disorders associated with misregulated eif4e |
| CA2943659C (en) * | 2014-03-27 | 2023-04-25 | Merck Patent Gmbh | Pyridyl piperidines |
| WO2016169886A1 (en) | 2015-04-24 | 2016-10-27 | Syngenta Crop Protection Ag | Pesticidally active polycyclic derivatives with sulfur substituted five-membered ring heterocyles |
| JP6707630B2 (ja) * | 2015-06-01 | 2020-06-10 | バンタム、ファーマシューティカル、リミテッド、ライアビリティー、カンパニーＢａｎｔａｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌ， Ｌｌｃ | 置換ピラゾールおよびピロール化合物、および翻訳開始の阻害およびこれらに関連する疾患および障害の治療のためにこれらを用いる方法 |
| BR112019011035A2 (pt) * | 2016-11-30 | 2019-10-15 | Bantam Pharmaceutical Llc | métodos de uso de compostos pirazol e pirazol substituído e para o tratamento de doenças hiperproliferativas |
| AU2017366901B2 (en) * | 2016-11-30 | 2022-09-29 | Bantam Pharmaceutical, Llc | Substituted pyrazole compounds and methods of using them for treatment of hyperproliferative diseases |
| CA3142196A1 (en) * | 2019-05-31 | 2020-12-03 | Bantam Pharmaceutical, Llc | Crystalline polymorphs of a 1-thiazol-2-yl-pyrazole-5-carboxylic acid derivative |
-
2017
- 2017-11-29 AU AU2017366901A patent/AU2017366901B2/en active Active
- 2017-11-29 CN CN202410345199.5A patent/CN118930533A/zh active Pending
- 2017-11-29 JP JP2019528861A patent/JP7373992B2/ja active Active
- 2017-11-29 CA CA3081983A patent/CA3081983A1/en active Pending
- 2017-11-29 US US16/465,136 patent/US11325903B2/en active Active
- 2017-11-29 IL IL266930A patent/IL266930B2/en unknown
- 2017-11-29 MX MX2019006299A patent/MX2019006299A/es unknown
- 2017-11-29 NZ NZ754827A patent/NZ754827A/en unknown
- 2017-11-29 WO PCT/US2017/063774 patent/WO2018102453A1/en not_active Ceased
- 2017-11-29 CN CN201780084999.4A patent/CN110603254B/zh active Active
- 2017-11-29 BR BR112019011044-5A patent/BR112019011044A2/pt active Search and Examination
- 2017-11-29 EP EP17876486.6A patent/EP3548482A4/en active Pending
-
2022
- 2022-05-10 US US17/741,153 patent/US20230076820A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20230076820A1 (en) | 2023-03-09 |
| NZ754827A (en) | 2025-10-31 |
| RU2019120233A3 (enExample) | 2021-03-11 |
| EP3548482A1 (en) | 2019-10-09 |
| US20190345152A1 (en) | 2019-11-14 |
| WO2018102453A1 (en) | 2018-06-07 |
| BR112019011044A2 (pt) | 2019-10-08 |
| IL266930B2 (en) | 2025-09-01 |
| IL266930A (en) | 2019-07-31 |
| JP7373992B2 (ja) | 2023-11-06 |
| MX2019006299A (es) | 2019-11-12 |
| AU2017366901B2 (en) | 2022-09-29 |
| EP3548482A4 (en) | 2020-08-19 |
| IL266930B1 (en) | 2025-05-01 |
| CN110603254B (zh) | 2024-04-12 |
| US11325903B2 (en) | 2022-05-10 |
| CN118930533A (zh) | 2024-11-12 |
| RU2019120233A (ru) | 2021-01-11 |
| CN110603254A (zh) | 2019-12-20 |
| JP2019536785A (ja) | 2019-12-19 |
| AU2017366901A1 (en) | 2019-07-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA3081983A1 (en) | Substituted pyrazole compounds and methods of using them for treatment of hyperproliferative diseases | |
| AU2022201688B2 (en) | Compounds as nuclear transport modulators and uses thereof | |
| US8999982B2 (en) | Pharmaceutically active compounds as Axl inhibitors | |
| AU2017376624B2 (en) | Aminothiazole compounds as c-Kit inhibitors | |
| US11634395B2 (en) | Sulfonamide compound or salt thereof | |
| JP5744288B2 (ja) | キノキサリン誘導体 | |
| JP2011500657A (ja) | 組合せ０５９ | |
| JP2022137047A5 (enExample) | ||
| JP2008528467A5 (enExample) | ||
| KR20140138911A (ko) | Ｍｅｋ 억제제로서 헤테로사이클릴 화합물 | |
| JPWO2009054468A1 (ja) | アゾールカルボキサミド化合物又はその塩 | |
| JP2017510642A5 (enExample) | ||
| EP2916841A1 (en) | Combination therapy | |
| TWI585087B (zh) | Novel tetrahydropyridine pyrimidine compounds or salts thereof | |
| US20200405697A1 (en) | Antitumor Agent | |
| RU2014118677A (ru) | Ингибиторы киназ типа polo | |
| ES2849560T3 (es) | Derivados de 2,4-diamino-quinolina sustituidos para su uso en el tratamiento de enfermedades proliferativas | |
| US10889555B2 (en) | Sulfonamide compound or salt thereof | |
| JP2011513419A5 (enExample) | ||
| JP2021080266A (ja) | モルヒナン誘導体のオピオイドδ受容体アゴニスト関連疾患の治療のための使用 | |
| CA2851383A1 (en) | 2 - carboxamide cycloamino urea derivatives in combination with hsp90 inhibitors for the treatment of proliferative diseases | |
| JPWO2019236966A5 (enExample) | ||
| NZ770629A (en) | Pyridopyrimidinone derivatives for use as axl inhibitors | |
| NZ770629B2 (en) | Pyridopyrimidinone derivatives for use as axl inhibitors | |
| JP2015534975A5 (enExample) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20221128 |
|
| EEER | Examination request |
Effective date: 20221128 |
|
| EEER | Examination request |
Effective date: 20221128 |